Abiopharma

🔍 FRANCIS LAURA (Executive)

Company: SI-BONE, Inc. (SIBN)

Report Date: 2026-08-20

Detailed Transactions and Holdings:

• Sold 51,884 shares of Common Stock at $19.46 per share (Direct)
  Date: 2026-08-20 | Code: S | equity_swap_involved: false | shares_owned_after: 321,386.00 | transaction_form_type: 4 | Footnotes: F1, F2, F3
• Sold 3,923 shares of Common Stock at $20.02 per share (Direct)
  Date: 2026-08-21 | Code: S | equity_swap_involved: false | shares_owned_after: 317,463.00 | transaction_form_type: 4 | Footnotes: F1, F4, F3
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-08-20 | Code: H | shares_owned_after: 493,900.00 | Footnotes: F5

Footnotes:

• F1: The sale reported on this Form 4 was effected pursuant to a 10b5-1 trading plan dated May 21, 2026.
• F2: The price reported in column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $19.10 to $19.73, inclusive. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes.
• F3: Shares held by The David & Laura Joint Rev Tr.
• F4: The price reported in column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $20.00 to $20.05, inclusive. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes.
• F5: Includes 355,697 shares issuable on settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one shares of the Issuer's common stock.